BlossomHill, VogenX and Latigo reveal IPO plans
Three more biotechs have revealed their intentions to list on Nasdaq – BlossomHill, VogenX, and Latigo – as 2026 continues on a path to become a record-shattering year for IPOs on the exchange.
BlossomHill seeks funds for phase 2 cancer trials
BlossomHill Therapeutics closed an $84 million Series B just a few months ago, but has moved swiftly ahead with plans for an IPO, filing confidentially in April and publicly revealing its intention in a prospectus filed with the SEC on Friday.
The San Diego-based company is raising funds for phase 2 trials of two small-molecule drugs for cancer - OMNI-EGFR inhibitor BH-30643 and CLK inhibitor BH-30236 – which are in early-stage clinical testing, respectively for EGFR-mutated non-small cell lung cancer (NSCLC) and elapsed or refractory acute myeloid leukaemia (AML) and higher-risk myelodysplastic syndrome (MDS).
According to its prospectus, BlossomHill is also hoping to raise funds to advance a preclinical-stage pan-KRAS asset into clinical testing. The company plans to list on the Nasdaq under the BLSM symbol.
VogenX has international plans for Kissei SGLT1 drug
Raleigh, North Carolina-headquartered VogenX is hoping to raise around $75 million in its IPO, under the VOGX symbol, according to Renaissance Capital. It is seeking additional funds for the development of a small-molecule SGLT1 inhibitor, mizagliflozin, which it licenses from Japan's Kissei Pharma.
The candidate, which is designed to block the transport of glucose from the gastrointestinal tract into the blood and reduce insulin secretion, has completed phase 2 testing in post-bariatric hypoglycaemia (PBH) – the dangerously low blood glucose levels that can occur after eating in some patients who have surgery for weight loss. A phase 2b trial is scheduled to start later this year, along with a phase 2 trial in gastroparesis, a chronic condition in which stomach emptying takes place too slowly.
VogenX is also developing mizagliflozin for GIP-dependent Cushing's syndrome, also known as food-dependent Cushing's, which leads to elevated levels of cortisol. And following after the SGLT1 inhibitor is VGX-2857, a preclinical-stage drug with an undisclosed mechanism that is being assessed for metabolic diseases, including weight maintenance after substantial weight loss.
Latigo charts course for non-opioid pain drug
Latigo Biotherapeutics is working on a non-opioid pain reliever acting as an oral Nav1.8 inhibitor – in the same class as Vertex Pharma's first-to-market Journavx (suzetrigine) – which has just shown promising analgesic efficacy in a phase 2 trial in patients undergoing abdominoplasty surgery. The drug, LTG-001, outperformed an opioid analgesic (Vicodin) in the head-to-head trial.
The planned IPO would provide additional funds for a phase 3 trial in bunionectomy patients and an open-label safety trial, due to start later this year, which would be combined with the abdominoplasty readout in a filing for a moderate-to-severe acute pain indication, possibly in 2027.
The company, which intends to list under the LTGO symbol, is also working on an intravenous formulation of LTG-001 as well as a follow-up Nav1.8 inhibitor (LTG-418) in preclinical development.
